Advances in Chronic Urticaria: Biomarkers, Comorbidities, Therapeutic Strategies, and Patient‑Reported Outcomes

Chronic urticaria (CU) is a heterogeneous mast cell-driven inflammatory skin disorder characterized by recurrent wheals, angioedema, and/or pruritus lasting longer than six weeks. It includes chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), which differ in their clinical presentation, triggering factors and underlying mechanisms. The pathophysiology of CU encompasses complex immune mechanisms, including autoantibody‑driven mast cell activation and dysregulated cytokine signaling. Emerging endotypes include autoimmune, autoallergic, and non-autoimmune forms. Despite progress in understanding these pathways, translating biological insights into clinically useful biomarkers remains a major challenge. Current and emerging therapies, ranging from second-generation H1-antihistamines to targeted biologics, have transformed management. However, treatment responses vary widely, emphasizing the need for better predictors of disease activity, remission, and therapeutic success.At the same time, patient‑reported outcome measures (PROMs) have become essential for capturing disease burden, quality of life, and the subjective dimensions of symptom control that are not fully reflected by clinical or laboratory parameters. Integrating PROMs with biomarker data and therapeutic outcomes offers a promising route toward more holistic, personalized care.This Research Topic aims to unify mechanistic, translational, clinical, and patient‑centered research to advance the understanding and management of CU. Contributions may address biomarker discovery, disease endotyping, novel therapeutic approaches, predictive modeling, real‑world treatment outcomes, and innovations in disease monitoring, including digital tools and longitudinal PROM‑based assessment. By fostering collaboration across dermatology, allergy, immunology, and related disciplines, this Topic seeks to accelerate progress toward precision medicine and improved quality of life for patients with CU.We welcome submissions addressing, but not limited to:• Immune and molecular mechanisms underlying CSU and CIndU• Diagnostic, prognostic, and treatment-response biomarkers• Omics‑based approaches to endotyping and disease stratification• Clinical trial data and real‑world evidence on current and emerging therapies• Predictive modeling of treatment response and remission• Integration of PROMs with biological and clinical endpoints• CU-associated comorbidities and their impact on disease course and management• Innovations in disease monitoring, digital health tools and quality‑of‑life assessmentArticle types: Original Research, Review, Mini Review, Hypothesis and Theory, Case Report, and Clinical Trial reports.- Mojca Bizjak-Suran is or recently was a speaker and advisor for Novartis. - Pavel Kolkhir has received research funding as a speaker/consultant for Novartis and Sanofi/Regeneron. He is on the Advisory Board for ALK. - Ivan Cherrez-Ojeda is or recently was a speaker for Zaval.- Melba Munoz is or recently was a speaker/consultant and/or advisor for and/or has received research funding from Annexon, Biocryst, Blueprint, Celltrion, Celldex, Jasper Therapeutics, Novartis and Roche. Topic editors: Pavel Kolkhir, Mojca Bizjak-Suran, Ivan Cherrez-Ojeda, Melba Munoz Source: https://www.frontiersin.org/research-topics/83203/advances-in-chronic-urticaria-biomarkers-comorbidities-therapeutic-strategies-and-patient-reported-outcomes